Pressure BioSciences, Inc.
14 Norfolk Avenue
South Easton,
MA 02375
United States - Map
Phone: 508-230-1828
Fax: 508-230-1829
Web Site: http://www.pressurebiosciences.com
| Pressure BioSciences, Inc. (PBI) focuses on the development and commercialization of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. The company holds 13 U.S. and 6 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical (primarily enzymatic) reactions, immunodiagnostics, and protein purification. PBI focuses on the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications. It serves academic laboratories; government agencies; and biotechnology, pharmaceutical, and life science companies. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2004 as a result of change in business strategy. Pressure BioSciences, Inc. was founded in 1978 and is based in South Easton, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Richard T. Schumacher , 58
Founder, Chief Exec. Officer, Pres, Principal Financial Officer, Principal Accounting Officer,Treasurer |
N/A
| N/A | Dr. Edmund Y. Ting Sc.D. Ph.D., 54
Sr. VP of Engineering |
$
191.00K | N/A | Mr. Ted Myles MBA, 37
Consultant |
$
184.00K | N/A | Dr. Nathan P. Lawrence Ph.D., 54
VP of Marketing and Sales |
$
146.00K | N/A | Dr. Alexander V. Lazarev Ph.D., 44
VP of R&D |
$
141.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.22% Nasdaq 
Profile
